TS
PRAX icon

Thomas Steyer’s Praxis Precision Medicines PRAX Stock Holding History

Thomas Steyer’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$3.05M – 181
2024
Q1 		$3.05M Buy
+50,000
New +$2.24M 0.01% 109
2021
Q1 		– Sell
-16,667
Closed -$13.8M – 246
2020
Q4 		$13.8M Buy
+16,667
New +$9.73M 0.08% 99

Other funds holding PRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Thomas Steyer's PRAX Position: Q2 2024 in Review

Thomas Steyer sold out of Praxis Precision Medicines (PRAX) in Q2 2024, closing a stake of 50,000 shares — an estimated $3.05M sold.

Thomas Steyer first reported a position in PRAX in Q4 2020 and held it in 2 quarters. The position peaked at $13.8M in Q4 2020. 113 funds tracked by Wall St. Rank hold PRAX as of Q2 2024.

  • Thomas Steyer reported no remaining Praxis Precision Medicines position as of Q2 2024 after selling out during the quarter.
  • Thomas Steyer sold 50,000 Praxis Precision Medicines shares in Q2 2024, an estimated $3.05M.
  • Thomas Steyer first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 2 quarters.
  • Thomas Steyer's Praxis Precision Medicines position peaked at $13.8M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.